Cardiology

New data from EPI Lifestyle Conference 2020 is shedding light on the impact of initiating estradiol therapy closer to the onset of menopause.

A 42-year-old man visited the ED complaining of acute onset of dizziness, heart palpitations, and a racing heartbeat. He's been working overtime and drinking caffeinated energy drinks to stay awake. He said he had multiple episodes of faintness over a short period of time. Can you diagnose this patient?

An analysis of 180,000 patients in South Korea is shedding new light on the potential poor oral hygiene can have on a person's risk of diabetes.

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.

Analysis of more than 13k patients from Taiwan found a vegetarian diet was linked to a lower risk of incident stroke events later in life.

A discussion on how to approach the real-world application of bempedoic acid with the Chief of Cardiology at Baylor College of Medicine.

The non-statin, fixed-dose combination therapy received approval less than one week after bempedoic acid received approval for treatment of HeFH.

The approval is the second non-statin LDL-C lowering therapy from Esperion to receive approval in the month of February.

Early menopause onset has been linked to increased CVD risk, but a new study from England is examining whether age of onset has a role in worsening risk factors.

The approval allows Zynex to market CM-1500, a blood monitoring system aimed at helping doctors monitor various patient parameters.

Results of the LINK-HF study indicate a wearable sensors from Vital Connect combined with a predictive algorithm can predict HF exacerbations.

A fourth-year medical student discusses strategies for anticoagulation reversal in intensive care units from a presentation during the 49th Annual Critical Care Congress in Orlando.

New data from a study of 30 patients found specific characteristics of gut microbiota could predict the presence of pulmonary hypertension with greater than 80% accuracy.

With approval, the GLP-1 receptor agonist becomes the first diabetes drug approved for reducing MACE in patients with and without established cardiovascular.

The approval of bempedoic acid (Nexletol) marks the first oral, non-statin therapy approved by the FDA as a lipid-lowering agent in nearly 20 years.

Clinical trial data for the lipid-lowering non-statin agent indicates it can lower LDL-C by as much as 18% when combined with maximally tolerated statins.

A secondary analysis of patients with prior stroke, TIA, or thromboembolism from AUGUSTUS is revealing more about the use of apixaban in patients with AFib.

New data indicates a combination of 3 natural extracts added to standard therapy could provide benefits in patients with uncontrolled hypertension.